Woman scientist in lab look at science microscope medical test and research biology chemistry. Females technician laboratory analyzing scientific pharmacy genetic research. Chemistry Medical test lab
Humans develop sharp vision during early fetal development through a complex interplay between a vitamin A derivative and thyroid hormones in the retina, according to groundbreaking research from Johns Hopkins University. This discovery could revolutionize the understanding of eye growth and pave the way for new treatments for age-related vision disorders such as macular degeneration and glaucoma.
The findings, detailed in the Proceedings of the National Academy of Sciences, reveal how lab-grown retinal tissue can be used to study the development of light-sensing cells. “This is a key step toward understanding the inner workings of the center of the retina,” said Robert J. Johnston Jr, an associate professor of biology at Johns Hopkins and the study’s lead researcher. “By better understanding this region and developing organoids that mimic its function, we hope to one day grow and transplant these tissues to restore vision.”
Revolutionizing Eye Research with Organoids
The research team has pioneered a novel method to study eye development using organoids, which are small clusters of tissue grown from fetal cells. By observing these lab-grown retinas over several months, the researchers uncovered the cellular mechanisms that shape the foveola, a central retinal region crucial for sharp vision.
Their study, partially funded by the National Institutes of Health, focused on the light-sensitive cells responsible for daytime vision. These cells develop into blue, green, or red cone cells, each sensitive to different types of light. Although the foveola comprises only a small fraction of the retina, it accounts for approximately 50% of human visual perception, containing red and green cones but not blue cones, which are more broadly distributed across the retina.
Understanding Unique Human Vision
Humans are unique in possessing three types of cones for color vision, allowing them to perceive a wide spectrum of colors, a trait relatively rare in the animal kingdom. The distribution of these cells and their development have puzzled scientists for decades, as traditional research models like mice and fish do not exhibit the same cellular patterning.
The Johns Hopkins team discovered that the distribution of cones in the foveola results from a coordinated process of “cell fate specification” and conversion during early development. Initially, a sparse number of blue cones are present in the foveola at weeks 10 through 12 of fetal development. By week 14, these blue cones transform into red and green cones.
The Role of Vitamin A and Thyroid Hormones
The study identifies two key processes in this transformation. First, a molecule derived from vitamin A, known as retinoic acid, is broken down to limit the creation of blue cones. Second, thyroid hormones facilitate the conversion of blue cones into red and green cones. “First, retinoic acid helps set the pattern. Then, thyroid hormone plays a role in converting the leftover cells,” Johnston explained. “That’s very important because if you have those blue cones in there, you don’t see as well.”
These findings challenge the prevailing theory that blue cones migrate to other parts of the retina during development. Instead, the data suggest that these cells convert to achieve optimal cone distribution in the foveola. “The main model in the field from about 30 years ago was that somehow the few blue cones you get in that region just move out of the way,” Johnston said. “We can’t really rule that out yet, but our data supports a different model. These cells actually convert over time, which is really surprising.”
Implications for Future Treatments
The implications of this research are significant, offering new insights into the development of photoreceptors and potential cell-based treatments for eye diseases like macular degeneration, which currently have no cure. The ability to grow and potentially transplant retinal tissue could transform the landscape of vision restoration therapies.
As the scientific community continues to explore these findings, the potential for breakthroughs in treating vision disorders becomes increasingly promising. The Johns Hopkins team’s work not only enhances our understanding of eye development but also opens new avenues for medical innovation.
